GSK said on Monday (Dec 18) that a combination of its cancer drugs Zejula and Jemperli, when used as a maintenance therapy following Jemperli plus chemotherapy, met the main goal of a late-stage trial to treat a certain type of endometrial cancer.
GSK said on Monday (Dec 18) that a combination of its cancer drugs Zejula and Jemperli, when used as a maintenance therapy following Jemperli plus chemotherapy, met the main goal of a late-stage trial to treat a certain type of endometrial cancer.